β-elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter

Guo,Hui-Qin; Zhang,Guan-Nan; Wang,Yi-Jun; Zhang,Yun-Kai; Sodani,Kamlesh; Talele,Tanaji  T.; Ashby,Charles  R.; Chen,Zhe-Sheng

doi:10.3892/or.2013.2870

β-elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter

Authors:
- Hui-Qin Guo
- Guan-Nan Zhang
- Yi-Jun Wang
- Yun-Kai Zhang
- Kamlesh Sodani
- Tanaji T. Talele
- Charles R. Ashby
- Zhe-Sheng Chen
View Affiliations

Affiliations: Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA
Published online on: November 27, 2013 https://doi.org/10.3892/or.2013.2870
Pages: 858-866

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present in vitro study, we examined the effect of the compound β-elemene on the response of KB-C2 cells overexpressing the ABCB1 transporter to specific antineoplastic compounds. The MTT assay was used to determine the effects of β-elemene in combination with other anticancer drugs on ABCB1-overexpressing cancer cell lines. Furthermore, we used [3H]-paclitaxel accumulation, efflux assay, immunofluorescence experiments, western blot assays and docking analysis to ascertain the mechanism of action of β-elemene. The incubation of KB-C2 cells overexpressing ABCB1 transporter with β-elemene (100 µM) significantly augmented the antineoplastic efficacy of colchicine, vinblastine and paclitaxel when compared to KB-C2 cells incubated with these drugs alone. In HEK293 cells overexpressing the ABCB1 transporter, β-elemene significantly increased the cytotoxicity of paclitaxel. In addition, 100 µM of β-elemene significantly increased the accumulation of [3H]-paclitaxel and this was due to a decrease in [3H]-paclitaxel efflux when compared to controls. The incubation of KB-C2 cells with β-elemene (100 µM) for 72 h did not significantly alter the expression of ABCB1 protein levels. Immunofluorescence experiments indicated that β-elemene did not significantly alter the subcellular localization of the ABCB1 transporter. Docking analysis indicated that β-elemene binds to the drug-binding site of ABCB1 transporter. Finally, β-elemene at 100 µM partially (~50%) increased the sensitivity of the BCRP-overexpressing cell line, NCI-H460/MX20, to mitoxantrone, but β-elemene did not significantly alter the resistance of MRP1-transfected HEK293/MRP1 cells to vincristine. Overall, our in vitro findings indicated that β-elemene potentiates the cytotoxic effects of various antineoplastic drugs in cell lines overexpressing the ABCB1 transporter and that this is due to the inhibition of the efflux component of the ABCB1 transporter.

View Figures

View References

1	Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
2	Goldstein LJ, Gottesman MM and Pastan I: Expression of the MDR1 gene in human cancers. Cancer Treat Res. 57:101–119. 1991.
3	Vasiliou V, Vasiliou K and Nebert DW: Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 3:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
4	Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
5	Perez-Victoria JM, Di Pietro A, Barron D, Ravelo AG, Castanys S and Gamarro F: Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets. 3:311–333. 2002. View Article : Google Scholar : PubMed/NCBI
6	Sauna ZE, Kim IW and Ambudkar SV: Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr. 39:481–487. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dean M and Annilo T: Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet. 6:123–142. 2005. View Article : Google Scholar : PubMed/NCBI
8	Janssen IJ, Krücken J, Demeler J, Basiaga M, Kornaś S and von Samson-Himmelstjerna G: Genetic variants and increased expression of Parascaris equorum P-glycoprotein-11 in populations with decreased ivermectin susceptibility. PLoS One. 8:e616352013.PubMed/NCBI
9	Shen DW, Lu YG, Chin KV, Pastan I and Gottesman MM: Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci. 98:317–322. 1991.PubMed/NCBI
10	Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR and Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 38:1277–1287. 1990. View Article : Google Scholar : PubMed/NCBI
11	Wu CP, Calcagno AM and Ambudkar SV: Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
12	Robert J and Jarry C: Multidrug resistance reversal agents. J Med Chem. 46:4805–4817. 2003. View Article : Google Scholar
13	Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol. 12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
14	Dantzig AH, de Alwis DP and Burgess M: Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev. 55:133–150. 2003. View Article : Google Scholar : PubMed/NCBI
15	Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 43:2267–2272. 1983.PubMed/NCBI
16	de Souza PS, da Cunha Vasconcelos F, Silva LF and Maia RC: Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells. Tumour Biol. 33:943–956. 2012.PubMed/NCBI
17	Shukla S, Wu CP and Ambudkar SV: Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol. 4:205–223. 2008. View Article : Google Scholar : PubMed/NCBI
18	Leonard GD, Polgar O and Bates SE: ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs. 3:1652–1659. 2002.PubMed/NCBI
19	Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P and Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51:4226–4233. 1991.PubMed/NCBI
20	Germann UA, Shlyakhter D, Mason VS, et al: Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 8:125–140. 1997. View Article : Google Scholar
21	Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283. 2000.PubMed/NCBI
22	Müller H, Pajeva IK, Globisch C and Wiese M: Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 16:2448–2462. 2008.PubMed/NCBI
23	Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F and Dumontet C: Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 48:708–715. 2007.PubMed/NCBI
24	van Zuylen L, Sparreboom A, van der Gaast A, et al: Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer. 38:1090–1099. 2002.PubMed/NCBI
25	Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M and Mayer LD: Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144–193, by human liver microsomes. Eur J Drug Metab Pharmacokinet. 26:273–282. 2001.PubMed/NCBI
26	Zhou HY, Shen JK, Hou JS, Qiu YM and Luo QZ: Experimental study on apoptosis induced by elemene in glioma cells. Ai Zheng. 22:959–963. 2003.(In Chinese).
27	Zou L, Liu W and Yu L: beta-elemene induces apoptosis of K562 leukemia cells. Zhonghua Zhong Liu Za Zhi. 23:196–198. 2001.(In Chinese).
28	Li QQ, Wang G, Zhang M, Cuff CF, Huang L and Reed E: β-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep. 22:161–170. 2009.
29	Hu J, Jin W and Yang PM: Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by β-elemene. Zhonghua Zhong Liu Za Zhi. 26:268–270. 2004.(In Chinese).
30	Biedler JL and Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30:1174–1184. 1970.PubMed/NCBI
31	Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 455:152–162. 1976. View Article : Google Scholar : PubMed/NCBI
32	Akiyama S, Fojo A, Hanover JA, Pastan I and Gottesman MM: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet. 11:117–126. 1985. View Article : Google Scholar : PubMed/NCBI
33	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 47:943–946. 1987.PubMed/NCBI
34	Sodani K, Tiwari AK, Singh S, et al: GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 83:1613–1622. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tiwari AK, Sodani K, Dai CL, et al: Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 328:307–317. 2013. View Article : Google Scholar : PubMed/NCBI
36	Sun YL, Chen JJ, Kumar P, et al: Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One. 8:e555762013. View Article : Google Scholar : PubMed/NCBI
37	Aller SG, Yu J, Ward A, et al: Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 323:1718–1722. 2009. View Article : Google Scholar : PubMed/NCBI
38	Shi Z, Tiwari AK, Shukla S, et al: Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 71:3029–3041. 2011. View Article : Google Scholar : PubMed/NCBI
39	Dai CL, Tiwari AK, Wu CP, et al: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
40	Ding PR, Tiwari AK, Ohnuma S, et al: The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 6:e193292011. View Article : Google Scholar : PubMed/NCBI
41	Huang XC, Sun YL, Salim AA, Chen ZS and Capon RJ: Parguerenes: marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Biochem Pharmacol. 85:1257–1268. 2013. View Article : Google Scholar : PubMed/NCBI
42	Patel A, Tiwari AK, Chufan EE, et al: PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother Pharmacol. 72:189–199. 2013. View Article : Google Scholar : PubMed/NCBI
43	Xu HB, Li L, Fu J, Mao XP and Xu LZ: Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene. Pharmacology. 89:303–312. 2012.PubMed/NCBI